Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
(Contains description of formulation, indications, dosing, and storage recommendations)
The 28.7% average weight loss at 68 weeks surpasses anything else in the pipeline
Enhanced local blood supply supports the metabolic demands of repair
Published 2023 Jan 20
Semaglutide: FDA-approved for weight management (2021) and type 2 diabetes Widely available via prescription Available from research peptide suppliers Established insurance coverage pathways Years of post-marketing safety data Cagrilintide: Not FDA-approved (investigational as of March 2026) Phase 3 REDEFINE trials complete with positive results Available from some research peptide suppliers as a research chemical No insurance coverage Limited long-term safety data (68 weeks maximum from trials) Cost Considerations Without FDA approval, cagrilintide has no established retail price
Support Recovery, Joint Health & Tissue Repair
US$ 24.43
US$ 20.78
US$ 26.69
US$ 21.60
US$ 22.46
US$ 25.90
